Takara Bio (Takara Bio) FCF Margin % : 4.52% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Takara Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Takara Bio's Free Cash Flow for the three months ended in Mar. 2024 was $4.2 Mil. Takara Bio's Revenue for the three months ended in Mar. 2024 was $91.9 Mil. Therefore, Takara Bio's FCF Margin % for the quarter that ended in Mar. 2024 was 4.52%.

As of today, Takara Bio's current FCF Yield % is -9.20%.

The historical rank and industry rank for Takara Bio's FCF Margin % or its related term are showing as below:

TKBIF' s FCF Margin % Range Over the Past 10 Years
Min: -25.65 Med: 4.4 Max: 39.69
Current: -25.63

During the past 13 years, the highest FCF Margin % of Takara Bio was 39.69%. The lowest was -25.65%. And the median was 4.40%.

TKBIF's FCF Margin % is ranked better than
66.99% of 1039 companies
in the Biotechnology industry
Industry Median: -139.09 vs TKBIF: -25.63

Takara Bio FCF Margin % Historical Data

The historical data trend for Takara Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takara Bio FCF Margin % Chart

Takara Bio Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

Get a 7-Day Free Trial

6.62

11.06

-8.20

39.69

-25.65

Takara Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															120.57	-11.89	-83.03	-22.97	4.52

Competitive Comparison of Takara Bio's FCF Margin %

For the Biotechnology subindustry, Takara Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takara Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Takara Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Takara Bio's FCF Margin % falls into.

Takara Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Takara Bio's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	-74.497	/	290.385
	=	-25.65 %

Takara Bio's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	4.151	/	91.918
	=	4.52 %

Takara Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Takara Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Takara Bio (Takara Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Takara Bio Inc (OTCPK:TKBIF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4974:Japan TF2:Germany

Address

Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, JPN, 520-0058

Website

http://www.takara-bio.co.jp

Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.

Takara Bio (Takara Bio) Headlines

No Headlines